Edition:
United States

NeuroVive Pharmaceutical AB (NVP.ST)

NVP.ST on Stockholm Stock Exchange

3.42SEK
7:39am EDT
Change (% chg)

-0.07kr (-2.01%)
Prev Close
3.49kr
Open
3.42kr
Day's High
3.50kr
Day's Low
3.42kr
Volume
12,085
Avg. Vol
406,766
52-wk High
7.45kr
52-wk Low
2.90kr

Latest Key Developments (Source: Significant Developments)

Neurovive Q1 pretax loss deepens
Thursday, 18 May 2017 02:30am EDT 

May 18 (Reuters) - Neurovive Pharmaceutical Ab :Q1 net revenues were sek 27,000 (0) and other operating income was sek 63,000 (46,000).Q1 loss before tax was sek 21,390,000 (loss: 10,916,000).  Full Article

NeuroVive Pharmaceutical enters into global licensing agreement with Yungjin Pharm
Monday, 1 May 2017 06:20pm EDT 

May 2 (Reuters) - Yungjin Pharm Co Ltd <003520.KS>::announced it has entered into global licensing agreement on Yungjin Pharm's compound KL1333 for genetic mitochondrial disorders.will now initiate activities in preparation for next clinical study in Europe and/or in U.S..NeuroVive will pay Yungjin Pharm upfront payments of $1 million at signing.NeuroVive will pay Yungjin Pharm additional $1 million after completion of a successful phase I clinical trial.  Full Article

Neurovive Q4 pretax loss doubles yr/yr
Tuesday, 21 Feb 2017 02:30am EST 

Neurovive Pharmaceutical AB :Q4 loss before tax was SEK 14.6 million (7.4).  Full Article

Neurovive Q2 loss narrows
Thursday, 18 Aug 2016 02:30am EDT 

Neurovive Pharmaceutical : Q2 loss before tax was SEK 12,059,000 (15,216,000) .Q2 net revenues were SEK 0 (2,502,000).  Full Article

NeuroVive says completes 10 pct acquisition of Isomerase Therapeutics
Monday, 15 Aug 2016 07:30am EDT 

NeuroVive Pharmaceutical AB : NeuroVive completes 10 percent acquisition of Isomerase Therapeutics .Says now completed acquisition includes approximately 5 percent further of shares in Isomerase through a 550 000 GBP cash payment.  Full Article

Neurovive Q1 loss before tax narrows to SEK 11 mln
Tuesday, 31 May 2016 02:36am EDT 

Neurovive Pharmaceutical AB : Q1 net revenues were SEK 0 (0) and other operating income was SEK 46,000 (49,000) . Q1 loss before tax was SEK 10,916,000 (14,271,000) For the original story click here: http://mb.cision.com/Main/6574/2019911/522487.pdf Further company coverage: [NVP.ST] (Stockholm Newsroom) ((stockholm.newsroom@thomsonreuters.com; +46 (0)8-700 10 10;)).  Full Article

Neurovive Pharmaceutical AB says insiders intend to subscribe for at least 5.4 million swedish crowns in rights issue
Tuesday, 26 Apr 2016 06:30am EDT 

Neurovive Pharmaceutical AB:Says insiders and employees intend to subscribe for a minimum of 5.4 million swedish crowns.Says that board members, other insiders and employees intend to subscribe for a minimum of 129 000 units, equivalent to at least 5.4 million swedish crowns, in the company's preferential rights issue with the subscription period between 18 April and 2 May.  Full Article

Neurovive Pharmaceutical AB announces Erik Kinnman new CEO
Tuesday, 23 Feb 2016 02:30am EST 

Neurovive Pharmaceutical AB:Says has selected Erik Kinnman as NeuroVive's Chief Executive Officer.Kinnman will assume the new role on March 14.  Full Article

Neurovive buys stake in Isomerase Therapeutics, issues new shares
Thursday, 14 Jan 2016 02:30am EST 

Neurovive Pharmaceutical AB:Buys stake in Isomerase Therapeutics.Says ‍acquires about 5 pct shares in Isomerase with payment in own shares​.Says ‍later this year Neurovive will acquire about 5 pct further of shares in Isomerase as a cash payment of 550,000 GBP.Says will issue 738,533 new shares, giving a purchase price for the first step amounting to about 6.8 million was based on the average closing price of NeuroVive shares on Nasdaq Stockholm from Dec. 23-Jan. 12.Says the Non-Cash Consideration entails a dilution of about 2.4 pct​.  Full Article

Neurovive says safety committee endorses continuation of CiPRICS study
Thursday, 19 Nov 2015 02:30am EST 

Neurovive Pharmaceutical AB:Says reports favorable safety evaluation in phase II acute kidney injury study.Says the independent safety committee has endorsed the continuation of the on-going Phase II CiPRICS (Ciclosporin to Protect Renal function In Cardiac Surgery) study following the enrollment of the first 50 patients in the study.  Full Article

More From Around the Web

BRIEF-Neurovive Q1 pretax loss deepens

* Q1 net revenues were sek 27,000 (0) and other operating income was sek 63,000 (46,000)